


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

1. **(Previously Presented)** A method for rescuing damaged nerve cells in a patient, comprising:

administering to a patient having damaged nerve cells an amount of a deprenyl compound, wherein the deprenyl compound is represented by the structure of Formula I:



wherein

R₁ is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, or aryloxy carbonyl;

R₂ is hydrogen or alkyl;


R₃ is a single bond, alkylene, or $-(\text{CH}_2)_n-\text{X}-(\text{CH}_2)_m$;

in which X is O, S, or N-methyl; m is 1 or 2; and n is 0, 1, or 2;

R₄ is alkyl, alkenyl, alkynyl, heterocyclyl, aryl or aralkyl; and

R₅ is alkylene, alkenylene, alkynylene and alkoxy lene; and

R₆ is C₃-C₆ cycloalkyl or



R₂ and R₄-R₃ are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;

and pharmaceutically acceptable salts thereof;


such that rescuing of damaged nerve cells occurs in the patient;

with the proviso that the deprenyl compound is not selected from the group consisting of deprenyl, pargyline, AGN-1133, or AGN1135.

2. **(Cancelled)**


3. **(Previously Presented)** The method of claim 1, wherein R₁ is a group that can be removed *in vivo*.

4. **(Previously Presented)** The method of claim 1, wherein R_1 is hydrogen.
5. **(Previously Presented)** The method of claim 1, wherein R_1 is alkyl.
6. **(Original)** The method of claim 5, wherein R_1 is methyl.
7. **(Previously Presented)** The method of claim 1, wherein R_2 is methyl.
8. **(Previously Presented)** The method of claim 1, wherein R_3 is methylene.
9. **(Previously Presented)** The method of claim 1, wherein R_4 is aryl.
10. **(Previously Presented)** The method of claim 1, wherein R_4 is phenyl.
11. **(Previously Presented)** The method of claim 1, wherein R_5 is methylene.
12. **(Previously Presented)** The method of claim 1, wherein R_6 is
$$-C\equiv CH$$
13. **(Previously Presented)** The method of claim 1, wherein the deprenyl compound has the structure



wherein R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, or aryloxy carbonyl.


14. **(Previously Presented)** The method of claim 1, wherein the deprenyl compound is represented by the structure:



in which

- R₁ is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, or aryloxy carbonyl;
- R₂ is hydrogen or alkyl;
- R₃ is a bond or methylene; and
- R₄ is aryl or aralkyl; or
- R₂ and R₄-R₃ are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;
- and pharmaceutically acceptable salts thereof.


15. **(Previously Presented)** The method of claim 1, wherein the deprenyl compound is represented by the structure:



in which

- R₂ is hydrogen or alkyl;
- R₃ is a bond or methylene; and
- R₄ is aryl or aralkyl; or
- R₂ and R₄-R₃ are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group; and
- R₅ is alkylene, alkenylene, alkynylene and alkoxylenes;
- and pharmaceutically acceptable salts thereof.

16. **(Previously Presented)** The method of claim 1, wherein the deprenyl compound is represented by the structure:



in which

R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, or aryloxy carbonyl;

A is a substituent independently selected for each occurrence from the group consisting of halogen, hydroxyl, alkyl, alkoxy, cyano, nitro, amino, carboxyl, $-CF_3$, or azido;

n is 0 or an integer from 1 to 5;

and pharmaceutically acceptable salts thereof.

17. **(Original)** The method of claim 1, wherein the deprenyl compound is (-)-desmethyldeprenyl.

18. **(Cancelled)**